A study investigating the safety of RO7795081 and the effect of RO7795081 on how the body processes different approved medications. RO7795081 is a new compound that may potentially be used in the treatment of type 2 diabetes and weight control

2024-519277-18-00 Protocol BP45800 Human pharmacology (Phase I) - Other Ongoing, recruiting

Start 8 May 2025 · Status Ongoing, recruiting · 1 EU/EEA countries · 1 sites · Protocol BP45800

Overview

Sponsor-declared trial summary

Phase Human pharmacology (Phase I) - Other
Status Ongoing, recruiting
Participants planned 40
Countries 1
Sites 1

Obesity or Overweight

Key facts

Sponsor
F. Hoffmann-La Roche AG
Participant type
Healthy volunteers
Age range
18-64 years
Gender
Male and Female
Therapeutic area
Diseases [C] - Nutritional and Metabolic Diseases [C18]
Trial duration
8 May 2025 → ongoing
Decision date (initial)
2025-04-17
Transition trial
No
Low-intervention
No
Rare-disease indication
No
Vulnerable population
Yes

Trial design

CTIS Part I — objectives, methods, condition coding

Conditions and MedDRA coding

Obesity or Overweight

VersionLevelCodeTermSystem organ class
24.1 PT 10033307 Overweight 100000004861
20.0 PT 10029883 Obesity 100000004861

Sponsors and contacts

Sponsor organisations, regulatory contacts, third parties

F. Hoffmann-La Roche AG

Sponsor organisation
F. Hoffmann-La Roche AG
Address
Grenzacherstrasse 124
City
Basel
Postcode
4058
Country
Switzerland

Scientific contact point

Organisation
F. Hoffmann-La Roche AG
Contact name
Trial Information System - TISL

Public contact point

Organisation
F. Hoffmann-La Roche AG
Contact name
Trial Information System - TISL

Locations

1 EU/EEA country · 1 investigational sites

By country

CountryMS statusPlanned subjectsSites
Netherlands Ongoing, recruiting 40 1
Rest of world 0

Investigational sites

Netherlands

1 site · Ongoing, recruiting
Pharma Bio-Research Group
Program Management, Van Swietenlaan 6, 9728 NZ, Groningen

Country notifications

Trial-start, recruitment-start, end and early-termination notifications submitted per Member State

Country Trial startTrial end Recruitment startRecruitment end Early termination
Netherlands 2025-05-08 2025-05-08

Application history

5 submissions — initial application plus substantial / non-substantial modifications

#TypeCodeSubmittedReference MSConclusionDecision date
1 INITIAL IN 2025-02-24 Netherlands Acceptable
2025-04-16
2025-04-17
2 SUBSTANTIAL MODIFICATION SM-1 2025-07-24 Netherlands Acceptable
2025-07-30
2025-07-31
3 NON SUBSTANTIAL MODIFICATION NSM-1 2025-12-10 Netherlands Acceptable
2025-07-30
2025-12-10
4 SUBSTANTIAL MODIFICATION SM-5 2026-03-13 Netherlands Acceptable 2026-03-20
5 SUBSTANTIAL MODIFICATION SM-7 2026-04-16 Netherlands Acceptable
2026-05-21
2026-05-21